IMS offers a robust and global source of oncology assets. Our anonymized patient-level oncology information, now covering 7 major markets worldwide, provides a complete view of the patient’s treatment history—from entering the healthcare system, to navigating through various stages of medical intervention.
The integration of these insights with other IMS information, such as global sales and prescription data, provides clients the evidential databases needed to make informed decisions throughout the oncology product lifecycle.